Real-World Oncological Outcomes of Nivolumab Plus Ipilimumab in Advanced or Metastatic Renal Cell Carcinoma: A Multicenter, Retrospective Cohort Study in Japan
Current Oncology · 2024
DOI: 10.3390/curroncol31120583 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Current Oncology, 2024. Verfasst von Tomoki Taniguchi und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Graduate School of Medicine, Gifu University, 1-1 Yanagido, Gifu 501-1194, Japan. Hauptthemen laut MEDLINE: Nivolumab, Ipilimumab, Carcinoma, Renal Cell, Kidney Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
A combination of nivolumab and ipilimumab (NIVO + IPI) is the only approved combination of two immune checkpoint inhibitors for metastatic or advanced renal cell carcinoma (mRCC). Inadequate evidence of treatment with NIVO + IPI has been reported in Japanese cohorts. We evaluated the clinical efficacy of NIVO + IPI treatment. Patients with mRCC who received NIVO + IPI at nine Japanese facilities between August 2018 and March 2023 were enrolled in this study. The primary endpoint in this study was the assessment of oncological outcomes in patients with mRCC who received NIVO + IPI. Eighty-four patients with mRCC were enrolled. The median follow-up period was 18.3 months, and median progression-free and overall survival were 13.3 and 50.9 months, respectively. The objective response rate was 47.6%, and the disease control rate was 78.6%. To our knowledge, this is the largest study that evaluates Japanese patients with mRCC receiving NIVO + IPI treatment. In this study, the real-world oncological outcomes after NIVO + IPI treatment were comparable to those in the CheckMate 214 study.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Graduate School of Medicine, Gifu University, 1-1 Yanagido, Gifu 501-1194, Japan.
- Department of Urology, Ogaki Municipal Hospital, 4-86 Minaminokawa-cho, Ogaki 503-8502, Japan.
- Department of Urology, Gifu Prefectural General Medical Center, 4-6-1 Noisiki, Gifu 500-8717, Japan.
- Department of Urology, Gifu Municipal Hospital, 7-1 Kashima-cho, Gifu 500-8513, Japan.
- Department of Urology, Daiyukai Hospital, 1-9-9 Sakura, Ichinomiya 491-8551, Japan.
ORCID-Profile: Tomoki Taniguchi, Makoto Kawase, Kota Kawase, Takuya Koie
Zitieren
APA
Taniguchi, T., Iinuma, K., Kawada, K., Ishida, T., Takagi, K., Tomioka, M., Kawase, M., Kawase, K., Nakane, K., Tobisawa, Y., & Koie, T. (2024). Real-World Oncological Outcomes of Nivolumab Plus Ipilimumab in Advanced or Metastatic Renal Cell Carcinoma: A Multicenter, Retrospective Cohort Study in Japan. Current Oncology. https://doi.org/10.3390/curroncol31120583
Vancouver
Taniguchi T, Iinuma K, Kawada K, Ishida T, Takagi K, Tomioka M, et al. Real-World Oncological Outcomes of Nivolumab Plus Ipilimumab in Advanced or Metastatic Renal Cell Carcinoma: A Multicenter, Retrospective Cohort Study in Japan. Current Oncology. 2024. doi:10.3390/curroncol31120583
BibTeX
@article{Taniguchi2024,
author = {Taniguchi, Tomoki and Iinuma, Koji and Kawada, Kei and Ishida, Takashi and Takagi, Kimiaki and Tomioka, Masayuki and Kawase, Makoto and Kawase, Kota and Nakane, Keita and Tobisawa, Yuki and Koie, Takuya},
title = {Real-World Oncological Outcomes of Nivolumab Plus Ipilimumab in Advanced or Metastatic Renal Cell Carcinoma: A Multicenter, Retrospective Cohort Study in Japan},
journal = {Current Oncology},
year = {2024},
doi = {10.3390/curroncol31120583}
}
EUVIMED